Browse by Phase
Phase 3 Clinical Trials
Phase 3 trials compare a new drug or treatment against the current standard of care in a large population (300–3,000+ participants). Successful Phase 3 results are the basis for regulatory approval.
Total Trials
537
Recruiting Now
537
Top Conditions in Phase 3
Frequently Asked Questions — Phase 3 Trials
Why are Phase 3 trials the standard for drug approval?
Phase 3 trials compare a new treatment against the current standard of care in a large, randomized population of 300–3,000+ participants. This large-scale comparative evidence is what regulatory agencies—FDA, EMA—require to approve a new drug. A successful Phase 3 trial demonstrates that the new treatment is more effective, safer, or both compared to existing options in a statistically significant, reproducible way.
What is a placebo control in a Phase 3 trial?
Many Phase 3 trials use a placebo control—a group that receives an inactive substance—to isolate the true effect of the treatment. When an established standard of care exists, control-arm participants typically receive that treatment rather than a placebo, for ethical reasons. Blinded designs prevent participants and investigators from knowing who received which treatment, reducing bias in outcome assessment.
How do I find and join a Phase 3 clinical trial?
ClinicalMetric lists all Phase 3 trials registered on ClinicalTrials.gov. Each trial card shows recruitment status, enrollment target, sponsor, conditions studied, and site locations. To join a Phase 3 trial, review the eligibility criteria and contact the trial site directly—usually an academic medical center or hospital. Your physician can facilitate a referral to the appropriate study site.
Active Phase 3 Studies
NCT07208591 Phase 3
Recruiting
To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acut...
Condition
Acute Respiratory Distress Syndrome (ARDS)
Enrollment
406 pts
Location
China
Sponsor
Staidson (Beijing) Biopharmace
NCT07265297 Phase 3
Recruiting
Using Hydroxychloroquine (HCQ) to Treat Steatohepatitis
Condition
Steatohepatitis, Nonalcoholic
Enrollment
210 pts
Location
Taiwan
Sponsor
National Taiwan University Hos
NCT07190196 Phase 3
Recruiting
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adul...
Condition
Immunoglobulin G4 Related Disease
Enrollment
124 pts
Location
United States, Argentina, Belgium
Sponsor
Sanofi
NCT07516132 Phase 3
Recruiting
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in...
Condition
Neovascular Age-Related Macular Degeneration (nAMD)
Enrollment
850 pts
Location
United States
Sponsor
Ocular Therapeutix, Inc.
NCT06269900 Phase 3
Recruiting
Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill ...
Condition
Hospital Acquired Pneumonia
Enrollment
450 pts
Location
France, Greece, Spain
Sponsor
Nantes University Hospital
NCT07019363 Phase 3
Recruiting
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk...
Condition
Breast Cancer
Enrollment
1,903 pts
Location
China
Sponsor
Fudan University
NCT07578363 Phase 3
Recruiting
An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction ...
Condition
Ocular Hyperemia
Enrollment
178 pts
Location
United States
Sponsor
Alcon Research
NCT06229483 Phase 3
Recruiting
The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Crani...
Condition
Brain Tumor
Enrollment
102 pts
Location
Canada
Sponsor
Stephen Lownie
NCT07739654 Phase 3
Recruiting
Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell ...
Condition
DLBCL - Diffuse Large B Cell Lymphoma
Enrollment
74 pts
Location
Pakistan
Sponsor
King Edward Medical University
NCT05552222 Phase 3
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR)...
Condition
Multiple Myeloma
Enrollment
1,590 pts
Location
United States, Australia, Austria
Sponsor
Janssen Research & Development
NCT07231419 Phase 3
Recruiting
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With ...
Condition
Diabetic Peripheral Neuropathic Pain
Enrollment
734 pts
Location
United States
Sponsor
Vertex Pharmaceuticals Incorpo
NCT06963034 Phase 3
Recruiting
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizoph...
Condition
Schizophrenia
Enrollment
284 pts
Location
United States
Sponsor
Neurocrine Biosciences
NCT07481799 Phase 3
Recruiting
Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Pos...
Condition
Oligo-metastatic Cancer
Enrollment
200 pts
Location
China
Sponsor
Ming-Yuan Chen
NCT06268652 Phase 3
Recruiting
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physi...
Condition
Breast Cancer
Enrollment
302 pts
Location
China
Sponsor
Sun Yat-sen University
NCT07489131 Phase 3
Recruiting
Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participa...
Condition
Diabetic Macular Edema
Enrollment
256 pts
Location
Hungary
Sponsor
Alvotech Swiss AG
NCT06102395 Phase 3
Recruiting
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy i...
Condition
Head and Neck Squamous Cell Carcinoma
Enrollment
272 pts
Location
China
Sponsor
Beijing Tongren Hospital
NCT04047628 Phase 3
Recruiting
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for ...
Condition
Relapsing Multiple Sclerosis
Enrollment
156 pts
Location
United States
Sponsor
National Institute of Allergy
NCT06307665 Phase 3
Recruiting
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As ...
Condition
Asthma
Enrollment
440 pts
Location
United States, China, Mexico
Sponsor
AstraZeneca
NCT07754539 Phase 3
Recruiting
A Study to Evaluate 20vPnC in Healthy Chinese Infants
Condition
Pneumococcal Diseases
Enrollment
1,250 pts
Location
China
Sponsor
Pfizer
NCT07782957 Phase 3
Recruiting
A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared...
Condition
Nasal Polyps
Enrollment
218 pts
Location
United States, Australia
Sponsor
GlaxoSmithKline
NCT07840365 Phase 3
Recruiting
Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage ...
Condition
Atrial Fibrillation (AF)
Enrollment
234 pts
Location
United States
Sponsor
Texas Cardiac Arrhythmia Resea
NCT07836530 Phase 3
Recruiting
Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellula...
Condition
Hepatocellular Carcinoma
Enrollment
492 pts
Location
Australia, New Zealand
Sponsor
BeOne Medicines
NCT05814432 Phase 3
Recruiting
Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histo...
Condition
Disseminated Histoplasma Capsulatum Infection
Enrollment
279 pts
Location
Brazil
Sponsor
Federal University of Health S
NCT05794971 Phase 3
Recruiting
Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Li...
Condition
Colorectal Cancer Liver Metastases
Enrollment
126 pts
Location
China
Sponsor
Sun Yat-sen University
NCT05758831 Phase 3
Recruiting
RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
Condition
Multiple Sclerosis
Enrollment
386 pts
Location
France
Sponsor
Rennes University Hospital
Page 1 of 22 — 537 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology